Targeting MSUT2 with small molecules to ameliorate pathological TAU

Active Grant Awarded

Award ID
R01AG078335
Recipient
Awarding agency
Obligated
$688,382

Award facts

Assistance listing
93.866 Aging Research
Completion date 9% complete
Place of performance
Seattle, WA 98108, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute on Aging, awarded Seattle Institute For Biomedical And Clinical Research (doing business as Seattle Institute) $688,382 under Grant R01AG078335 on September 16, 2026, funded through the Aging Research program (CFDA 93.866). The award funds research on small-molecule inhibitors of MSUT2, a protein whose binding to poly(A) RNA the project hypothesizes drives tau pathology in frontotemporal lobar degeneration, Alzheimer's disease, and related tauopathies. Its specific aims are to optimize potent, specific, brain-penetrant MSUT2 inhibitors, generate MSUT2-specific tool compounds, and demonstrate proof-of-concept therapeutic approaches to treating tauopathy. The total obligated amount is $688,382, with an ultimate completion date of August 31, 2028, and work is performed in Seattle, Washington 98108. The recipient's profile associates this MSUT2 project with sub-awards to the University of Pennsylvania and UC San Diego for compound synthesis and pharmacokinetic assessments. The Aging Research program encourages biomedical, social, and behavioral research on the aging process and its diseases, with a National Institute on Aging emphasis on preventing and treating Alzheimer's disease and related dementias.

Description

Abstract
In frontotemporal lobar degeneration, alzheimer's disease (ad) and related tauopathies, TAU neuropathology correlates with severity of dementia. However, interventions for ad and ad related dementias (ADRDS) are largely limited to treatment of symptoms that do not directly alter TAU pathology or the resultant neurodegeneration, with only one AΒ-directed immunotherapeutic (ADUHELM) recently receiving a controversial accelerated approval for disease modification. Although investigation into additional AΒ targeted immunotherapies continues, the obvious need remains for the development of TAU-targeted disease-modifying therapeutics. Our work has demonstrated that MSUT2 controls neuronal susceptibility to TAU toxicity in the mammalian brain. The mechanism of MSUT2 modulation of tauopathy involves the MSUT2 ccch domain binding to poly(a) RNA, as deletion of the ccch domain prevents neurodegeneration in animal models of tauopathy. High throughput screening of over 100,000 high diversity compounds has identified many active dose- responsive compounds that inhibit MSUT2 poly(a) RNA binding activity, including several classes of compounds exhibiting promising structure-activity relationships. The identification of drug-like small molecules that inhibit MSUT2 binding to poly(a) RNA will provide a pharmacological means of intervening against tauopathy. We hypothesize that small-molecule inhibitors of MSUT2/poly(a) RNA binding will slow or reverse TAU pathology and the toxic consequences of pathological TAU. The specific aims of this proposal are to optimize potent and specific brain-penetrant MSUT2 inhibitors and use them to demonstrate proof-of-concept therapeutic approaches to treating tauopathy. Successful completion of these aims will set the stage for future translational studies by both generating MSUT2 specific tool compounds and further validating a novel therapeutic target for pharmacological intervention in tauopathy disorders.

Quick answers

Who received award R01AG078335?

R01AG078335 was awarded to Seattle Institute For Biomedical And Clinical Research by National Institute on Aging (National Institutes of Health) on September 16, 2026.

How much is award R01AG078335 worth?

$688,382 has been obligated on R01AG078335.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award